Ask AI
ProCE Banner Activity

CLARITY: Day 190 Results of Injection-Site Reactions With Long-acting Injectable ART in Adults Without HIV

Conference Coverage
Slideset

In an open-label, randomized, crossover trial to assess participant experiences with long-acting injectable ART, injection-site reactions (ISRs) were more severe and of longer duration after a single dose of lenacapavir (LEN) compared with a single dose of cabotegravir (CAB).

Released: March 02, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This program is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions